These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1066436)

  • 1. Effect of urokinase upon euglobulin lysis time and thrombin time.
    Lee TK; Huang SC; Lin SA; Chien LM
    Taiwan Yi Xue Hui Za Zhi; 1976 Mar; 75(03):190-7. PubMed ID: 1066436
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombin accelerating factor in various urokinase preparations.
    Takada A; Matsuda H; Urano T; Takada Y
    Thromb Res; 1979; 14(4-5):673-8. PubMed ID: 483262
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation and importance of the clot-promoting potential of urokinase].
    Morito T; Kuto M; Wada H; Urata T; Lee CJ; Deguchi K; Shirakawa S
    Nihon Ketsueki Gakkai Zasshi; 1983 May; 46(3):759-66. PubMed ID: 6351526
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase.
    Takada A; Urano T; Takada Y
    Thromb Haemost; 1979 Oct; 42(3):901-8. PubMed ID: 505405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained fibrinolytic activity in the euglobulin fraction induced by concomitant administration of urokinase and dextran sulphate.
    Matsuo O; Kawaguchi T; Kosugi T; Mihara H
    Thromb Res; 1978 Dec; 13(6):1125-30. PubMed ID: 749265
    [No Abstract]   [Full Text] [Related]  

  • 6. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 7. Shortened method for the determination of euglobulin lysis time employing Malayan pit viper venom.
    Starr T; Gertler MM
    Thromb Res; 1989 Jun; 54(5):511-7. PubMed ID: 2772869
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of dextran sulfate and tranexamic acid on the activation of plasminogen by urokinase.
    Takada Y; Takada A
    Thromb Res; 1979; 16(5-6):865-9. PubMed ID: 160629
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase.
    Moroz LA; Sniderman AD; Marpole DG
    N Engl J Med; 1979 Nov; 301(20):1100-4. PubMed ID: 158709
    [No Abstract]   [Full Text] [Related]  

  • 10. [Thrombolytic action of urokinase preparation covalently bound to modified thrombin].
    Maksimenko AV; Tishvhenko EG; Petrov AD; Orekhova NM; Ragimov SE
    Biull Eksp Biol Med; 1988 Sep; 106(9):322-4. PubMed ID: 3167185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A study of urokinase lysis time in patients with various renal diseases].
    Shimizu K; Kishi T; Ootaka M; Yamamoto J; Shibata M; Ban I; Sakai H; Kobayashi K
    Nihon Jinzo Gakkai Shi; 1982 Nov; 24(11):1233-41. PubMed ID: 6762457
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrinolysis in the pigeon (Columba livia).
    Ahmad N; Dube B; Agarwal GP; Dube R
    Thromb Haemost; 1979 Oct; 42(3):955-8. PubMed ID: 505408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on coagulation and fibrinolysis. III. Urokinase activated fibrinolysodynamicogram].
    Hu YM; Xue H; Wang KQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Jun; 4(3):133-6. PubMed ID: 6215134
    [No Abstract]   [Full Text] [Related]  

  • 14. Retrospective study on the efficacy of using urokinase therapy.
    Matsuo O; Kosugi T; Mihara H; Ohki Y; Matsuo T
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):684-8. PubMed ID: 506651
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of thrombolytic treatment on natural inhibitors of coagulation-fibrinolysis, with report of pulmonary embolic cases.
    Hasegawa H; Nagata H; Murakoshi T; Yamauchi M; Oguma Y; Kamishima K; Murao M
    Nihon Ketsueki Gakkai Zasshi; 1979 Feb; 42(1):79-83. PubMed ID: 425795
    [No Abstract]   [Full Text] [Related]  

  • 16. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
    Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of intraventricular blood clot with urokinase in a canine model: Part 2. In vivo safety study of intraventricular urokinase.
    Pang D; Sclabassi RJ; Horton JA
    Neurosurgery; 1986 Oct; 19(4):547-52. PubMed ID: 3491339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Euglobulin lysis time (ELT)].
    Kaizu K; Abe M
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():584-5. PubMed ID: 15658395
    [No Abstract]   [Full Text] [Related]  

  • 20. Vasodilation due to urokinase in the canine femoral circulation.
    Gurll NJ; Zinner MJ; Callahan W; Reynolds DG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):731-7. PubMed ID: 864605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.